Israel Center for Disease Control, Israel Ministry of Health, Tel Hashomer, Ramat Gan, Israel.
Pediatric Infectious Diseases Unit, Safra Children's Hospital, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.
Euro Surveill. 2024 Aug;29(32). doi: 10.2807/1560-7917.ES.2024.29.32.2300634.
BackgroundA new respiratory virus surveillance platform, based on nationwide hospital laboratory data, was established in Israel during the COVID-19 pandemic.AimWe aimed to evaluate the performance of this platform with respect to the detection of influenza and respiratory syncytial virus (RSV) from week 36 in 2020 to week 15 in 2023, and how it fits with the World Health Organization (WHO) mosaic surveillance framework.MethodsData of respiratory samples from hospitalised patients sent for laboratory confirmation of influenza virus or RSV from 25 general hospital laboratories nationwide were collected. We analysed the weekly number and percentage of samples positive for influenza virus or RSV vis-à-vis SARS-CoV-2 activity and compared data from the new surveillance platform with existing surveillance platforms. Using data in the new surveillance platform, we analysed early stages of a 2021 out-of-season RSV outbreak and evaluated the capabilities of the new surveillance system with respect to objectives and domains of the WHO mosaic framework.ResultsThe new hospital-laboratory surveillance platform captured the activity of influenza virus and RSV, provided crucial data when outpatient sentinel surveillance was not operational and supported an out-of-season RSV outbreak investigation. The new surveillance platform fulfilled important objectives in all three domains of the mosaic framework and could serve for gathering additional information to fulfil more domain objectives.ConclusionThe new hospital laboratory surveillance platform provided essential data during the COVID-19 pandemic and beyond, fulfilled important domain objectives of the mosaic framework and could be adapted for the surveillance of other viruses.
在 COVID-19 大流行期间,以色列建立了一个基于全国医院实验室数据的新型呼吸道病毒监测平台。
我们旨在评估该平台在 2020 年第 36 周至 2023 年第 15 周期间检测流感病毒和呼吸道合胞病毒(RSV)的性能,以及它如何符合世界卫生组织(WHO)马赛克监测框架。
收集了来自全国 25 家综合医院实验室的住院患者呼吸道样本,这些样本是为实验室确认流感病毒或 RSV 而送检的。我们分析了每周 SARS-CoV-2 活动中流感病毒或 RSV 阳性样本的数量和百分比,并将新监测平台的数据与现有监测平台进行了比较。利用新监测平台中的数据,我们分析了 2021 年一次季节性外 RSV 暴发的早期阶段,并评估了新监测系统在 WHO 马赛克框架的目标和领域方面的能力。
新的医院实验室监测平台捕捉到了流感病毒和 RSV 的活动,在门诊哨点监测无法运行时提供了重要数据,并支持了一次季节性外 RSV 暴发的调查。新的监测平台在马赛克框架的所有三个领域都实现了重要目标,并且可以收集额外的信息来实现更多的领域目标。
新的医院实验室监测平台在 COVID-19 大流行期间及以后提供了重要数据,实现了马赛克框架的重要目标,并可以适应其他病毒的监测。